NYLIM
OLMA icon

New York Life Investment Management’s Olema Pharmaceuticals OLMA Stock Holding History

New York Life Investment Management’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-133,157
Closed -$326K – 1331
2022
Q4 		$326K Buy
133,157
+15,008
+13% +$43.8K ﹤0.01% 1108
2022
Q3 		$326K Buy
118,149
+8,680
+8% +$36.8K ﹤0.01% 1068
2022
Q2 		$446K Buy
+109,469
New +$347K 0.01% 800

Other funds holding OLMA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

New York Life Investment Management's OLMA Position: Q1 2023 in Review

New York Life Investment Management sold out of Olema Pharmaceuticals (OLMA) in Q1 2023, closing a stake of 133,157 shares — an estimated $326K sold.

New York Life Investment Management first reported a position in OLMA in Q2 2022 and held it in 3 quarters. The position peaked at $446K in Q2 2022. 65 funds tracked by Wall St. Rank hold OLMA as of Q1 2023.

  • New York Life Investment Management reported no remaining Olema Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • New York Life Investment Management sold 133,157 Olema Pharmaceuticals shares in Q1 2023, an estimated $326K.
  • New York Life Investment Management first reported a position in Olema Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • New York Life Investment Management's Olema Pharmaceuticals position peaked at $446K in Q2 2022.
  • 65 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2023.

Based on New York Life Investment Management's 13F filing for Q1 2023, filed 8 May 2023.